387 related articles for article (PubMed ID: 33329350)
1. Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.
Lazaridis K; Tzartos SJ
Front Neurol; 2020; 11():596981. PubMed ID: 33329350
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
Lazaridis K; Tzartos SJ
Front Immunol; 2020; 11():212. PubMed ID: 32117321
[TBL] [Abstract][Full Text] [Related]
3. Improving laboratory diagnostics in myasthenia gravis.
Gastaldi M; Scaranzin S; Businaro P; Mobilia E; Benedetti L; Pesce G; Franciotta D
Expert Rev Mol Diagn; 2021 Jun; 21(6):579-590. PubMed ID: 33970749
[No Abstract] [Full Text] [Related]
4. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens.
Zisimopoulou P; Brenner T; Trakas N; Tzartos SJ
Autoimmun Rev; 2013 Jul; 12(9):924-30. PubMed ID: 23537507
[TBL] [Abstract][Full Text] [Related]
5. Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features.
Park KH; Waters P; Woodhall M; Lang B; Smith T; Sung JJ; Kim KK; Lim YM; Kim JE; Kim BJ; Park JS; Lim JG; Kim DS; Kwon O; Sohn EH; Bae JS; Yoon BN; Kim NH; Ahn SW; Oh J; Park HJ; Shin KJ; Hong YH
PLoS One; 2018; 13(3):e0193723. PubMed ID: 29518096
[TBL] [Abstract][Full Text] [Related]
6. Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen.
Stergiou C; Lazaridis K; Zouvelou V; Tzartos J; Mantegazza R; Antozzi C; Andreetta F; Evoli A; Deymeer F; Saruhan-Direskeneli G; Durmus H; Brenner T; Vaknin A; Berrih-Aknin S; Behin A; Sharshar T; De Baets M; Losen M; Martinez-Martinez P; Kleopa KA; Zamba-Papanicolaou E; Kyriakides T; Kostera-Pruszczyk A; Szczudlik P; Szyluk B; Lavrnic D; Basta I; Peric S; Tallaksen C; Maniaol A; Gilhus NE; Casasnovas Pons C; Pitha J; Jakubíkova M; Hanisch F; Bogomolovas J; Labeit D; Labeit S; Tzartos SJ
J Neuroimmunol; 2016 Mar; 292():108-15. PubMed ID: 26943968
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
Vakrakou AG; Karachaliou E; Chroni E; Zouvelou V; Tzanetakos D; Salakou S; Papadopoulou M; Tzartos S; Voumvourakis K; Kilidireas C; Giannopoulos S; Tsivgoulis G; Tzartos J
Front Immunol; 2023; 14():1212757. PubMed ID: 37564637
[TBL] [Abstract][Full Text] [Related]
8. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
Cordts I; Bodart N; Hartmann K; Karagiorgou K; Tzartos JS; Mei L; Reimann J; Van Damme P; Rivner MH; Vigneron A; Weis J; Schulz JB; Tzartos SJ; Claeys KG
J Neurol; 2017 Jun; 264(6):1193-1203. PubMed ID: 28516329
[TBL] [Abstract][Full Text] [Related]
9. Cortactin autoantibodies in myasthenia gravis.
Gallardo E; Martínez-Hernández E; Titulaer MJ; Huijbers MG; Martínez MA; Ramos A; Querol L; Díaz-Manera J; Rojas-García R; Hayworth CR; Verschuuren JJ; Balice-Gordon R; Dalmau J; Illa I
Autoimmun Rev; 2014 Oct; 13(10):1003-7. PubMed ID: 25193850
[TBL] [Abstract][Full Text] [Related]
10. Serological diagnosis of myasthenia gravis and its clinical significance.
Li Y; Peng Y; Yang H
Ann Transl Med; 2023 Apr; 11(7):290. PubMed ID: 37090043
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.
Phillips WD; Vincent A
F1000Res; 2016; 5():. PubMed ID: 27408701
[TBL] [Abstract][Full Text] [Related]
12. Roles of collagen Q in MuSK antibody-positive myasthenia gravis.
Ohno K; Otsuka K; Ito M
Chem Biol Interact; 2016 Nov; 259(Pt B):266-270. PubMed ID: 27119269
[TBL] [Abstract][Full Text] [Related]
13. Multiple antibody detection in 'seronegative' myasthenia gravis patients.
Hong Y; Zisimopoulou P; Trakas N; Karagiorgou K; Stergiou C; Skeie GO; Hao HJ; Gao X; Owe JF; Zhang X; Yue YX; Romi F; Wang Q; Li HF; Gilhus NE; Tzartos SJ
Eur J Neurol; 2017 Jun; 24(6):844-850. PubMed ID: 28470860
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.
Zhang B; Tzartos JS; Belimezi M; Ragheb S; Bealmear B; Lewis RA; Xiong WC; Lisak RP; Tzartos SJ; Mei L
Arch Neurol; 2012 Apr; 69(4):445-51. PubMed ID: 22158716
[TBL] [Abstract][Full Text] [Related]
15. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
Ohta R; Motomura M
Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
[TBL] [Abstract][Full Text] [Related]
16. [Myasthenia gravis: current status of antibody diagnostics and aspects on refractory myasthenia gravis].
Wenninger S; Schoser B
Fortschr Neurol Psychiatr; 2018 Sep; 86(9):551-558. PubMed ID: 30248688
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of cortactin antibodies in myasthenia gravis.
Illa I; Cortés-Vicente E; Martínez MÁ; Gallardo E
Ann N Y Acad Sci; 2018 Jan; 1412(1):90-94. PubMed ID: 29068555
[TBL] [Abstract][Full Text] [Related]
18. [Progress of myasthenia gravis: discovery of Lrp4 antibodies].
Motomura M; Higuchi O
Rinsho Shinkeigaku; 2012; 52(11):1303-5. PubMed ID: 23196599
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.
Cortés-Vicente E; Gallardo E; Martínez MÁ; Díaz-Manera J; Querol L; Rojas-García R; Illa I
JAMA Neurol; 2016 Sep; 73(9):1099-104. PubMed ID: 27379450
[TBL] [Abstract][Full Text] [Related]
20. Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.
Takamori M
Front Mol Neurosci; 2020; 13():86. PubMed ID: 32547365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
